Abstract:Objective To explore the time window of bevacizumab to normalize the vascular for tumor and analyze the efficacy of bevacizumab plus paclitaxel in lung cancer-bearing mice.Methods Athymic mice bearing A549 xenografts were constructed.The study can be divided into two parts.In first part, 24 nude mice were randomly assigned into two groups (n=12 per group): control group (intraperitoneal injection of saline) and bevacizumab group (intraperitoneal injection of bevacizumab 5 mg/kg).At four time points after injection (1, 3, 5, 8 d;n=3 at each time point), the volume of tumor and the weight of nude mice were measured.Meanwhile, the levels of vascular endothelial growth factor (VEGF) and microvessel density (MVD) in tumor tissues were detected by Western blotting and immunofluorescence methods, respectively.In second part, 30 nude mice were randomly divided into four groups: control group (n=5), bevacizumab monotherapy group (n=5), paclitaxel monotherapy group (n=5) and paclitaxel plus bevacizumab group (n=15).On the day of administration or the third and fifth day after administration of bevacizumab, paclitaxel plus bevacizumab group received intraperitoneal injection of paclitaxel with five mice at each time point.The paclitaxel and bevacizumab were administered at doses of 3 mg/kg and 5 mg/kg, respectively.The volumes of tumor were measured at 6 time points including 3, 7, 10, 14, 17, 20 days after administration.The nude mice were killed and the weight of tumor was measured 21 days later.The VEGF and MVD of the tumor were detected by Western blotting and immunohistochemistry.Results In the first part of our study, the tumor growth was suppressed gradually after the treatment of bevacizumab as compared with control group.Tumor volume, VEGF level and MVD reached a nadir at 3 days after bevacizumab administration.In the second part, compared with the control group, bevacizumab in combination with paclitaxel at different time points could suppress the tumor growth with a much significant inhibition effect on day 3 after bevacizumab administration.The average tumor volume, tumor weight, VEGF level and MVD were less in combined administration on day 3 than other combined groups.Conclusion The possible timing of the normalization window was typically 1-3 days after the administration of bevacizumab.The normalization window may provide an opportunity to enhance the effect of paclitaxel with the aid of bevacizumab.

The Sequence of Drug Administration Influences the Antitumor Effects of Bevacizumab and Cyclophosphamide in a Neuroblastoma Model

Effect of bevacizumab combined with chemotherapy at different sequences in the gastric-cancer-bearing nude mice

Bevacizumab Plays a double-edged role in Neoadjuvant Therapy for Non-metastatic Breast Cancer: A Systemic Review and Meta-Analysis

Investigation of Combination Therapy Modes of Bevacizumab and Paclitaxel for Nsclc in Vivo

Long-Term Relief of Cerebral Radiation Necrosis Treated with Low-Dose Bevacizumab - a Report of 2 Cases

Effect of bevacizumab on angiogenesis and related cytokines in mice with malignant pleural effusion

Experimental Study of Apoptosis in Leukemic Cell Lines Induced by Combined Use of Bevacizumab and Chemotherapeutic Drug

Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.

Synergistic Effects Of Bevacizumab In Combination With Beta-Elemene On Subcutaneous Xenografts Derived From Hct-116 Human Colon Cancer Cells

Experimental study of vascular normalization window for tumor induced by bevacizumab and efficacy of bevacizumab plus paclitaxel in lung cancer-bearing mice

Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells.

Bevacizumab Combined with Chemotherapy Vs Single-Agent Therapy in Recurrent Glioblastoma: Evidence from Randomized Controlled Trials

A Retrospective Analysis of Efficacy and Safety of Adding Bevacizumab to Chemotherapy As First- and Second-Line Therapy in Advanced Non-Small-cell Lung Cancer (NSCLC)

Long-Course Targeted Therapy with Bevacizumab to Predict Better Survival in Patients with Advanced Colorectal Cancer.

Efficacy of Neoadjuvant Chemotherapy Combined with Bevacizumab Versus Neoadjuvant Chemotherapy Alone for Her2-negative Breast Cancer:A Meta-Analysis of Randomized ;controlled Clinical Trials

Optimizing the Treatment of Bevacizumab As First-Line Therapy for Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Advanced Breast Cancer: an Updated Meta-Analysis of Published Randomized Trials

Effect of First-Line Bevacizumab on Prognosis of Second or Later-Line Immunotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Analysis.

Combination therapy of cRGD-DOX self-assembled nanoparticles and bevacizumab for breast cancer

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab.

Bevacizumab Monotherapy Reduces Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma Patients: A Randomized Controlled Trial